Crinetics Pharmaceuticals reported unaudited and preliminary net product revenue of over $5 million for the fourth quarter of 2025.
Atumelnant achieved a 67% mean reduction in Androstenedione levels while enabling 88% of participants to reduce Glucocorticoid dose to physiologic replacement levels.
The Phase 2 trial results showed positive outcomes with no hepatic transaminase adverse events.
Strong PALSONIFY Launch
PALSONIFY launch in acromegaly successful with over 200 enrollment forms after FDA approval.
Atumelnant Efficacy
Achieved significant reduction in Androstenedione levels and successful Glucocorticoid dose reduction in participants.
Benefit/Risk Profile
Atumelnant maintained a favorable benefit/risk profile with no serious adverse events.
- The positive results from the PALSONIFY launch and Phase 2 trial indicate a promising future for Crinetics Pharmaceuticals.
- The revenue generated and enrollment numbers reflect a strong market response to the company's products.
- The safety and efficacy data further support the potential of atumelnant as a treatment option for congenital adrenal hyperplasia.
Crinetics Pharmaceuticals is positioned for growth with the successful launch of PALSONIFY and promising clinical trial results for atumelnant.